Reprogenetics

s for any indication (aneuploidy, translocations, single gene disorders. Unlike other PGD laboratories, Reprogenetics does not just read the literature and implement new techniques developed by others – Reprogenetics creates the literature. It has been on the forefront of research since its inception, and has contributed to the majority of technologies now used in PGD laboratories. Reprogenetics also has historically maintained the lowest error rate in the industry for single cell assessment. This is the result of ongoing improvements to the cytogenetics laboratories, optimization of embryo biopsy and fixation procedures, and Reprogenetics’ continuous research efforts to improve genetic assessment. Reprogenetics spends nearly one quarter of its revenue on research related to developing new technologies, and enhancing existing ones. It is currently collaborating with more than 20 institutes to improve the future of PGD.